For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Baricitinib - Rheumatoid arthritis
PAD Profile : Baricitinib - Rheumatoid arthritis Important
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Abatacept
- Certolizumab pegol
- Etanercept
- Golimumab
- Penicillamine
- Rituximab
- Tocilizumab
- Adalimumab
- Sodium aurothiomalate
- Infliximab
- Tofacitinib
- Sarilumab
- Filgotinib
- Upadacitinib
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathway.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
The PCN recommends baricitinib as a treatment option for the treatment of severe Rheumatoid Arthritis in line with NICE TA466 Prescribing will be by hospital specialists only, in line with NICE TA466 using Blueteq initiation and continuation forms. Baricitinib will be considered RED on the traffic light system